{"id":"W4387826356","doi":"10.1016/j.annonc.2023.09.1132","title":"1902P Comparison of cabozantinib (CABO) versus sunitinib (SUN) following first-line (1L) nivolumab plus ipilimumab (NIVO+IPI) for metastatic renal cell carcinoma (mRCC): A target trial emulation using real-world data from the International mRCC Database Consortium (IMDC)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency; University of Calgary","funders":"Genentech; Ipsen; PharmaMar; Servier; European Society for Medical Oncology; Associazione Italiana per la Ricerca sul Cancro; Cilag; Astellas Pharma; Merck Sharp and Dohme; Eisai; Pfizer; Ministero della Salute; Chugai Pharmaceutical; Seagen; Karyopharm Therapeutics; Sanofi; Exelixis; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Amgen; Merck","keywords":"Medicine; Sunitinib; Internal medicine; Nivolumab; Ipilimumab; Proportional hazards model; Cabozantinib; Renal cell carcinoma; Hazard ratio; Oncology; Cancer; Immunotherapy; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009138344,0.001110365,0.00237708,0.0005440009,0.0001566906,0.001096954,0.001315787,0.001364578,0.0110755],"category_scores_gemma":[0.01503137,0.0004885521,0.005639633,0.0006070863,0.0005732742,0.00109048,0.0007303335,0.002170166,0.001075897],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001291622,"about_ca_system_score_gemma":0.001098271,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003788832,"about_ca_topic_score_gemma":0.002996878,"domain_scores_codex":[0.9964534,0.002839208,0.000116437,0.0002546217,0.0001445024,0.0001919604],"domain_scores_gemma":[0.9880233,0.00959267,0.001139472,0.0004742678,0.0002502311,0.0005200524],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.8850202,0.001965614,0.008600485,0.00126631,0.01413834,0.0002502507,0.00007146225,0.04303333,0.001258986,0.0009317903,0.009310521,0.03415276],"study_design_scores_gemma":[0.5311001,0.1528728,0.07586319,0.0006073348,0.0359317,0.001015657,0.0003030964,0.1813696,0.004213877,0.004096218,0.0124082,0.0002182074],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9665701,0.004027561,0.003428944,0.001609904,0.0003307723,0.0007600842,0.01750941,0.0001853716,0.005577854],"genre_scores_gemma":[0.9871048,0.0006273715,0.001103511,0.0002802009,0.00009784239,0.0004106392,0.008221828,0.00004758245,0.002106213],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0110755,"threshold_uncertainty_score":0.04832876,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.4345612815362631,"score_gpt":0.4358961580624438,"score_spread":0.001334876526180695,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}